Munich - Delayed Quote EUR

Nexstim Oyj (5NX.MU)

7.84

0.00

(0.00%)

At close: April 28 at 8:53:15 AM GMT+2

Nexstim Oyj (FRA:5NX) (Q4 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Nexstim Oyj (FRA:5NX) reports a 21% sales increase and positive EBITDA, driven by the successful launch of the NBS 6 therapy system and a pivotal partnership with Brainlab.

GuruFocus.com last month

5NX.F
Sinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025

CAMBRIDGE, Mass., January 15, 2025--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, today announced that co-development of the SinaptiStim® Neuromodulation System is underway, with planned March delivery of the first clinical system for validation testing and use in forthcoming clinical trials. Partner Nexstim (NXTMH:HEX) is customizing the

Business Wire 3 months ago

NXTMH.HE

BITTI.HE
Nexstim Oyj (FRA:5NX) (H1 2024) Earnings Call Highlights: Strong Revenue Growth and Improved ...

Nexstim Oyj (FRA:5NX) reports a 27% increase in net sales and significant improvements in operating results for the first half of 2024.

GuruFocus.com 6 months ago

5NX.F
Nexstim Receives NBS System 5 Order from European Customer

Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an existing customer. Nexstim’s NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for non-invasive mapping of the primary motor cortex of the brain. The system provides information that may be used in pre-procedural planning. In addition to the diagnostic features, t

GlobeNewswire 6 months ago

NXTMH.HE
Nexstim Receives Order for NBS System 5 in Finland

Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospital for an NBS System 5. The customer is new to Nexstim. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The system provides information that may be used in the assessment of the primary motor

GlobeNewswire 6 months ago

NXTMH.HE
New European Customer Orders Nexstim NBS System 5

Press release, Helsinki, 3 September 2024 at 9 AM (EEST) New European Customer Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new European customer through a distributor. The Nexstim Navigated Brain Stimulation (NBS) System 5 is the only FDA-cleared and CE-marked navigated TMS (Transcranial Magnetic Stimulation) system for pre-operative mapping of the motor and speech cortices of the brain. Mikko Karvinen, CEO of Nexs

GlobeNewswire 7 months ago

NXTMH.HE
NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)

Company announcement, Helsinki, August 16, 2024 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED) NEXSTIM CONTINUED TO GROW AND IMPROVED ITS PROFITABILITY IN THE FIRST HALF OF THE YEAR The figures in parentheses refer to the previous year’s comparative period, unless otherwise stated. January–June 2024 in brief The company’s net sales were EUR 3.2 million (2.5), with an increase of 26.9 %Net sales growth adjusted for currency exchange rates was 26.8 %System sales

GlobeNewswire 8 months ago

NXTMH.HE
Notice of Nexstim Plc’s Half-Year Report H1 2024

Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") will publish its half-yearly report for the six months ended 30 June 2024 on Friday 16 August 2024 at approximately 9:00 am Finnish time. The company will hold two live webinars for media, investors, and analysts on Friday 16 August 2024. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational results followed by

GlobeNewswire 8 months ago

NXTMH.HE
Nexstim Receives NBS System 5 Order from New European Customer

Press release, Helsinki, 10 July 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from New European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 through a distributor in Europe. The end customer is acquiring the system primarily for research purposes. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The NBS System 5 provides inf

GlobeNewswire 9 months ago

NXTMH.HE
US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems

Press release, Helsinki, 1 July 2024 at 11:30 AM (EEST) US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received an order and delivered two new NBS 6 systems to a private clinic customer in the United States. The customer is an experienced Nexstim system user that is now upgrading its existing systems at two clinic locations. Nexstim launched NBS 6, a new generation nTMS system, in 2023. The NBS 6 is cleared by

GlobeNewswire 9 months ago

NXTMH.HE
Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to Finance Product Development Project

Company Announcement, Helsinki, 27 June 2024 at 4:45 PM (EEST) Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to Finance Product Development Project Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has agreed on an EUR 1.5 million digitalization and innovation loan with Finnvera. The loan has been implemented in cooperation with the European Investment Fund. The Company intends to use the loan for financing product development work of its NBS 6 system. The loan peri

GlobeNewswire 9 months ago

NXTMH.HE
Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible bond has closed and EUR 650,000 of the bond was subscribed for

Company Announcement, Helsinki, 25 June 2024 at 9:30 AM (EEST) Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible bond has closed and EUR 650,000 of the bond was subscribed for NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Nexstim Plc (NXTMH:HEX) announces that it

GlobeNewswire 9 months ago

NXTMH.HE
Insider Information: Nexstim Plc launches an unsecured convertible bond offering of up to EUR 750,000

Company Announcement, Helsinki, 25 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc launches an unsecured convertible bond offering of up to EUR 750,000 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Nexstim Plc (NXTMH:HEX) (“Nexstim” or the “Company”) announces that its board of

GlobeNewswire 9 months ago

NXTMH.HE
Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Company announcement, Helsinki, 18 June 2024 at 11:30 AM (EEST) Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) has received a notification pursuant to chapter 9, section 5 of the Securities Market Act from Ossi Haapaniemi on 17 June 2024. The notification is based on the amendment to the Securities Market Act effective April 19, 2024, requiring shareholders to notify the target co

GlobeNewswire 10 months ago

NXTMH.HE
Insider Information: Nexstim Plc Provides Further Details on Technology License Agreement with Magnus Medical, Inc.

Company announcement, Helsinki, 12 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Provides Further Details on Technology License Agreement with Magnus Medical, Inc. Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces that it has disagreements regarding the licensing of the Company’s technology to medical technology company Magnus Medical, Inc. (”Magnus Medical”). The technology licensed is related to the NBT® system developed by the Company, with certain restrictions, and the r

GlobeNewswire 10 months ago

NXTMH.HE
Distributor Orders Nexstim NBS System 5 for European Hospital

Press release, Helsinki, 10 June 2024 at 9 AM (EEST) Distributor Orders Nexstim NBS System 5 for European Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a distributor for a European hospital. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech function. The informat

GlobeNewswire 10 months ago

NXTMH.HE
Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc.

Company announcement, Helsinki, 7 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc. Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has successfully negotiated and signed a Letter of Intent (LOI) to exclusively collaborate with Sinaptica Therapeutics, Inc. (“Sinaptica”) to develop, manufacture and supply Sinaptica’s patented precision neuromodulation system custom-based upon the Nexstim NBS 6

GlobeNewswire 10 months ago

NXTMH.HE
Finnish Hospital Orders Nexstim NBS System 5

Press release, Helsinki, 8 May 2024 at 9 AM (EEST) Finnish Hospital Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a hospital in Finland. This is a new customer to Nexstim. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The system provides information that may be used in the assessment of the primary motor corte

GlobeNewswire 11 months ago

NXTMH.HE
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD

Press release, Helsinki, 6 May 2024 at 9 AM (EEST) Health Canada Approves Nexstim NBS 6 System for Treatment of MDD Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received approval from Health Canada for the marketing and commercial distribution of its NBS 6 system for the treatment of Major Depressive Disorder (MDD). Released in the EU and the United States in 2023, the NBS 6 is a new generation Nexstim system. The NBS 6 is currently FDA-approved for the treatment of major depressive diso

GlobeNewswire 11 months ago

NXTMH.HE
Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market

Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has signed a non-exclusive strategic alliance agreement with Inomed Inc. for the purpose of strengthening the collaboration of Marketing, Sales, and Application Support between both companies in the United States. Both Nexstim and Inomed will attend the American Association of Neurologic

GlobeNewswire 11 months ago

NXTMH.HE

Performance Overview

Return	5NX.MU	OMX Helsinki_PI (^OMXHPI)
YTD	-5.08%	--
1-Year	+240.87%	--
3-Year	+103.64%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nexstim Oyj (5NX.MU)

Nexstim Oyj (FRA:5NX) (Q4 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Sinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025

Nexstim Oyj (FRA:5NX) (H1 2024) Earnings Call Highlights: Strong Revenue Growth and Improved ...

Nexstim Receives NBS System 5 Order from European Customer

Nexstim Receives Order for NBS System 5 in Finland

New European Customer Orders Nexstim NBS System 5

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)

Notice of Nexstim Plc’s Half-Year Report H1 2024

Nexstim Receives NBS System 5 Order from New European Customer

US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems

Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to Finance Product Development Project

Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible bond has closed and EUR 650,000 of the bond was subscribed for

Insider Information: Nexstim Plc launches an unsecured convertible bond offering of up to EUR 750,000

Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Insider Information: Nexstim Plc Provides Further Details on Technology License Agreement with Magnus Medical, Inc.

Distributor Orders Nexstim NBS System 5 for European Hospital

Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc.

Finnish Hospital Orders Nexstim NBS System 5

Health Canada Approves Nexstim NBS 6 System for Treatment of MDD

Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market

Performance Overview